Combination Radiotherapy for Recurrent Thyroid Cancer
This study is testing a combination treatment (CXRPT) of external beam radiation (XRT) and radioactive iodine (RAI) for people with recurrent thyroid cancer. The goal is to see if this combined approach can safely deliver higher doses of radiation to tumors than either treatment alone. You might be able to join if you are 18 to 85 years old and have papillary or follicular thyroid cancer that hasn't fully responded to previous treatments like surgery or radioactive iodine. The main way success will be measured is by looking at how safe the combined treatment is, specifically by tracking any side effects during and shortly after external beam radiation therapy. The current recruitment status for this study is unclear.
- Study design
- This is an open-label, Phase 1 interventional study aiming to enroll 48 participants. It will evaluate the safety of combining external beam radiation with radioactive iodine.
- What's involved
- Not specified in the trial record.
- Compensation
- Not stated in the trial record.
- Follow-up
- Safety will be measured during external beam radiation therapy (over a 2-week period) and within 30 days of completing external beam radiation therapy.
AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.
Combination Radiotherapy and Radiopharmaceutical Therapy Treatment Planning for Thyroid Cancer
At a glance
Conditions
Where it's being run
1 sites across 1 statesStudy leadership
- Harry Quon, MD · PRINCIPAL_INVESTIGATOR · Johns Hopkins, School of Medicine, Radiation Oncology
Who to contact
Opens a ready-to-send draft in your own email app — review before sending.
What this trial measures
- Safety of combined therapy of XRT plus RAI measured by NCI-CTCAE toxicityDuring external beam radiation therapy (over a 2 week period)
Toxicity of combined XRT plus RAI defined by the incidence of grade 3 or greater toxicities as measured with National Cancer Institutes-Common Terminology Criteria for Adverse Events (CTCAE)
- Safety of combined therapy of XRT plus RAI measured by NCI-CTCAE toxicityWithin 30 days of completing external beam radiation therapy
Toxicity of combined XRT plus RAI defined by the incidence of grade 3 or greater toxicities as measured with National Cancer Institutes-Common Terminology Criteria for Adverse Events (CTCAE)